Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1989 May;33(5):689–692. doi: 10.1128/aac.33.5.689

Comparative evaluation of daptomycin (LY146032) and vancomycin in the treatment of experimental methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits.

J T Mader 1, K Adams 1
PMCID: PMC172515  PMID: 2546488

Abstract

A rabbit model for methicillin-resistant Staphylococcus aureus (MRSA) osteomyelitis was used to compare treatment with daptomycin, a new peptolide, and vancomycin. Daptomycin (4 mg/kg) and vancomycin (40 mg/kg) were injected subcutaneously every 12 and 6 h, respectively. After treatment, MRSA was found in bone cultures from 18 of 18 control rabbits, 10 of 17 animals treated with daptomycin, and 11 of 18 animals treated with vancomycin. Drug concentrations were measured in serum, uninfected bone, and infected bone 1 h after daptomycin or vancomycin was injected in a group of rabbits that had been infected for 3 to 4 weeks. Vancomycin was present at the highest concentrations in infected and uninfected bone. The results of this study suggest that daptomycin was similar to vancomycin in the eradication of MRSA from infected bone in an experimental model of osteomyelitis.

Full text

PDF
689

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andrew J. H., Wale M. C., Wale L. J., Greenwood D. The effect of cultural conditions on the activity of LY146032 against staphylococci and streptococci. J Antimicrob Chemother. 1987 Aug;20(2):213–221. doi: 10.1093/jac/20.2.213. [DOI] [PubMed] [Google Scholar]
  2. Bayer A. S., Yih J., Hirano L. LY146032 compared with penicillin G in experimental aortic valve endocarditis caused by group G streptococci. Antimicrob Agents Chemother. 1988 Jan;32(1):141–143. doi: 10.1128/aac.32.1.141. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bush L. M., Boscia J. A., Kaye D. Daptomycin (LY146032) treatment of experimental enterococcal endocarditis. Antimicrob Agents Chemother. 1988 Jun;32(6):877–881. doi: 10.1128/aac.32.6.877. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Eliopoulos G. M., Thauvin C., Gerson B., Moellering R. C., Jr In vitro activity and mechanism of action of A21978C1, a novel cyclic lipopeptide antibiotic. Antimicrob Agents Chemother. 1985 Mar;27(3):357–362. doi: 10.1128/aac.27.3.357. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Eliopoulos G. M., Willey S., Reiszner E., Spitzer P. G., Caputo G., Moellering R. C., Jr In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic. Antimicrob Agents Chemother. 1986 Oct;30(4):532–535. doi: 10.1128/aac.30.4.532. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Ericsson H. M., Sherris J. C. Antibiotic sensitivity testing. Report of an international collaborative study. Acta Pathol Microbiol Scand B Microbiol Immunol. 1971;217(Suppl):1+–1+. [PubMed] [Google Scholar]
  7. Fass R. J., Helsel V. L. In vitro activity of LY146032 against staphylococci, streptococci, and enterococci. Antimicrob Agents Chemother. 1986 Nov;30(5):781–784. doi: 10.1128/aac.30.5.781. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Fitzpatrick D. J., Cafferkey M. T., Toner M., Beattie T., Keane C. T. Osteomyelitis with methicillin-resistant Staphylococcus aureus. J Hosp Infect. 1986 Jul;8(1):24–30. doi: 10.1016/0195-6701(86)90101-5. [DOI] [PubMed] [Google Scholar]
  9. Johnson K. D., Johnston D. W. Orthopedic experience with methicillin-resistant Staphylococcus aureus during a hospital epidemic. Clin Orthop Relat Res. 1986 Nov;(212):281–288. [PubMed] [Google Scholar]
  10. Klimek J. J., Marsik F. J., Bartlett R. C., Weir B., Shea P., Quintiliani R. Clinical, epidemiologic and bacteriologic observations of an outbreak of methicillin-resistant Staphylococcus aureus at a large community hospital. Am J Med. 1976 Sep;61(3):340–345. doi: 10.1016/0002-9343(76)90370-3. [DOI] [PubMed] [Google Scholar]
  11. Locksley R. M., Cohen M. L., Quinn T. C., Tompkins L. S., Coyle M. B., Kirihara J. M., Counts G. W. Multiply antibiotic-resistant Staphylococcus aureus: introduction, transmission, and evolution of nosocomial infection. Ann Intern Med. 1982 Sep;97(3):317–324. doi: 10.7326/0003-4819-97-3-317. [DOI] [PubMed] [Google Scholar]
  12. Mader J. T., Brown G. L., Guckian J. C., Wells C. H., Reinarz J. A. A mechanism for the amelioration by hyperbaric oxygen of experimental staphylococcal osteomyelitis in rabbits. J Infect Dis. 1980 Dec;142(6):915–922. doi: 10.1093/infdis/142.6.915. [DOI] [PubMed] [Google Scholar]
  13. Mader J. T., Wilson K. J. Comparative evaluation of cefamandole and cephalothin in the treatment of experimental Staphylococcus aureus osteomyelitis in rabbits. J Bone Joint Surg Am. 1983 Apr;65(4):507–513. [PubMed] [Google Scholar]
  14. Norden C. W. Experimental osteomyelitis. I. A description of the model. J Infect Dis. 1970 Nov;122(5):410–418. doi: 10.1093/infdis/122.5.410. [DOI] [PubMed] [Google Scholar]
  15. Norden C. W., Shaffer M. Treatment of experimental chronic osteomyelitis due to staphylococcus aureus with vancomycin and rifampin. J Infect Dis. 1983 Feb;147(2):352–357. doi: 10.1093/infdis/147.2.352. [DOI] [PubMed] [Google Scholar]
  16. Sheftel T. G., Mader J. T., Pennick J. J., Cierny G., 3rd Methicillin-resistant Staphylococcus aureus osteomyelitis. Clin Orthop Relat Res. 1985 Sep;(198):231–239. [PubMed] [Google Scholar]
  17. Sorrell T. C., Packham D. R., Shanker S., Foldes M., Munro R. Vancomycin therapy for methicillin-resistant Staphylococcus aureus. Ann Intern Med. 1982 Sep;97(3):344–350. doi: 10.7326/0003-4819-97-3-344. [DOI] [PubMed] [Google Scholar]
  18. Weeks J. L., Garcia-Prats J. A., Baker C. J. Methicillin-resistant Staphylococcus aureus osteomyelitis in a neonate. JAMA. 1981 Apr 24;245(16):1662–1664. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES